EMJ Hematology 9 [Supplement 4] . 2021

In this issue

At the 14th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), held virtually 3rd–5th February 2021, data on the efficacy, safety, pharmacokinetics, and pharmacoeconomics of damoctocog alfa pegol (Jivi®; BAY 94-9027; Bayer, Basel, Switzerland) in severe haemophilia were presented across five posters. Jivi is a site-specifically PEGylated, B-domain deleted recombinant factor VIII, with reduced clearance and extended time in circulation.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.